Vaxcyte, Inc. (PCVX) — SEC Filings
Vaxcyte, Inc. (PCVX) — 30 SEC filings. Latest: 10-Q (May 6, 2026). Includes 11 8-K, 8 SC 13G/A, 7 10-Q.
View Vaxcyte, Inc. on SEC EDGAR
Overview
Vaxcyte, Inc. (PCVX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 19, 2025: Vaxcyte, Inc. filed an 8-K on December 19, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits related to the period ending Decembe
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 27 neutral, 1 mixed. The dominant filing sentiment for Vaxcyte, Inc. is neutral.
Filing Type Overview
Vaxcyte, Inc. (PCVX) has filed 7 10-Q, 11 8-K, 2 DEF 14A, 2 10-K, 8 SC 13G/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of PCVX's 18 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$520.1M |
| EPS | -$3.83 |
| Debt-to-Equity | 0.10 |
| Cash Position | $281.1M |
| Operating Margin | N/A |
| Total Assets | $3.17B |
| Total Debt | $278.7M |
Key Executives
- George J. Incledon
- Dr. Sarah E. Fortune
- Dr. Sarah E. Bloch
- Dr. David L. Gordon
- Ms. Amy L. Peterson
- Abigail P. Johnson
Industry Context
Vaxcyte operates in the highly competitive biotechnology and pharmaceutical sector, specifically focusing on vaccine development. The market for vaccines, particularly for infectious diseases like pneumococcal disease, is driven by public health needs, government mandates, and the emergence of new pathogens or strains. Key trends include the development of novel vaccine technologies, such as mRNA and conjugate vaccines, and increasing demand for prophylactic measures against a wide range of diseases.
Top Tags
corporate-governance (5) · biotech (5) · financials (4) · Biotechnology (4) · 10-Q (4) · Vaxcyte (3) · PCVX (3) · Vaccine Development (2) · R&D Spending (2) · Net Loss (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Reporting Period End Date | 20251218 | The filing covers events and financial information up to this date. |
| Filing Date | 20251219 | The date the 8-K was officially submitted to the SEC. |
| Net Loss | $520.1M | Increased from $326.8M in 2024 for the nine months ended September 30 |
| Research and Development Expenses | $552.2M | Increased from $343.0M in 2024 for the nine months ended September 30 |
| Cash and Cash Equivalents | $281.1M | As of September 30, 2025, down from $387.9M at December 31, 2024 |
| Short-term Investments | $1.43B | As of September 30, 2025, up from $1.36B at December 31, 2024 |
| Net Cash Used in Operating Activities | $430.7M | For the nine months ended September 30, 2025, up from $341.2M in 2024 |
| Common Stock Shares Outstanding | 130,906,263 | As of October 31, 2025 |
| Net Loss Per Share (Diluted) | $1.56 | For the three months ended September 30, 2025, up from $0.83 in 2024 |
| Revenue | $0 | No revenue reported for Q2 2025 or YTD 2025, consistent with pre-commercial stage. |
| Net Loss (Q2 2025) | $105.2M | Increased from $85.1M in Q2 2024, reflecting higher R&D expenses. |
| Net Loss (YTD 2025) | $201.3M | Increased from $160.2M in YTD 2024, driven by accelerated clinical development. |
| R&D Expenses (Q2 2025) | $90.3M | Increased from $70.1M in Q2 2024, indicating significant investment in VAX-24 and VAX-31. |
| Net Proceeds from Public Offering | $300.0M | Raised in Q1 2025, bolstering cash reserves for ongoing operations and clinical trials. |
| Fiscal Year End | 2024 | The period covered by the compensation details in the filing. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant stake in Vaxcyte, Inc.","entity":"FMR LLC","targetDate":"Q4 2024","confidence":"high"}
- {"claim":"Vaxcyte's stock price will experience increased stability due to institutional backing.","entity":"Vaxcyte, Inc.","targetDate":"Q3 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Vaxcyte, Inc. (PCVX)?
Vaxcyte, Inc. has 30 recent SEC filings from Jan 2024 to May 2026, including 11 8-K, 8 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PCVX filings?
Across 30 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 27 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Vaxcyte, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vaxcyte, Inc. (PCVX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vaxcyte, Inc.?
Key financial highlights from Vaxcyte, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PCVX?
The investment thesis for PCVX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vaxcyte, Inc.?
Key executives identified across Vaxcyte, Inc.'s filings include George J. Incledon, Dr. Sarah E. Fortune, Dr. Sarah E. Bloch, Dr. David L. Gordon, Ms. Amy L. Peterson and 1 others.
What are the main risk factors for Vaxcyte, Inc. stock?
Of PCVX's 18 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Vaxcyte, Inc.?
Recent forward-looking statements from Vaxcyte, Inc. include guidance on {"claim":"FMR LLC will maintain a significant stake in Vaxcyte, Inc.","entity":"FMR LLC","targetDate":"Q4 2024","confide and 1 other predictions.